Meeting
2023 ASCO Annual Meeting
Integrated clinical, pathologic, and genetic data in a racially diverse hereditary breast cancer cohort.
Authors
Kenna Noel Koehler
Vanderbilt University Medical Center, Nashville, TN
Kenna Noel Koehler , KIKELOLA OYELEYE , Padma Sheila Rajagopal , Anne Weidner , Lindsay Venton , Jennifer Whisenant , Run Fan , Fei Ye , Tuya Pal , Sonya A. Reid
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Hereditary Cancer Syndromes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10553)
DOI
10.1200/JCO.2023.41.16_suppl.10553
Abstract #
10553
Poster Bd #
186
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
First Author: Channing Judith Paller
Poster
2023 ASCO Genitourinary Cancers Symposium
Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
First Author: Tanya Jindal
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Molecular genetic sequencing of neuroendocrine tumors of the gastrointestinal tract.
First Author: Alexandra Androsova
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye